Opioid-induced bowel dysfunction: Prevalence, pathophysiology and burden

International Journal of Clinical Practice

Volumn 61, Issue 7, 2007, Pages 1181-1187

  Panchal, S J ^a   Muller Schwefe P ^b   Wurzelmann, J I ^c  

^a National Institute of Pain and Coalition for Pain Education   (United States)

^b Universal Pain Institute   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; ANTACID AGENT; ANTIEMETIC AGENT; BISACODYL; CODEINE; DOCUSATE SODIUM; DOPAMINE RECEPTOR BLOCKING AGENT; ENEMA; FENTANYL; HISTAMINE H2 RECEPTOR ANTAGONIST; ISPAGULA; LACTULOSE; LAXATIVE; MACROGOL; MAGNESIUM SALT; METOCLOPRAMIDE; MORPHINE; OPIATE; PROTON PUMP INHIBITOR; SENNA EXTRACT; SEROTONIN ANTAGONIST; SORBITOL; TRAMADOL;

ABDOMINAL CRAMP; ABDOMINAL FULLNESS; ANALGESIA; BITTER TASTE; BLOATING; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; DAILY LIFE ACTIVITY; DEHYDRATION; DERMATITIS; DRUG INDUCED DISEASE; ELECTROLYTE DISTURBANCE; ENTEROPATHY; EXCESSIVE GAS; FECES; GAS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRANSIT; HUMAN; HYPERMAGNESEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; INTESTINE OBSTRUCTION; LOW DRUG DOSE; MEDLINE; MELANOSIS; MUSCLE SPASM; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; OPIOID INDUCED EMESIS; PATHOPHYSIOLOGY; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK; SIDE EFFECT; STOMACH EMPTYING; SYMPTOM;

ACTIVITIES OF DAILY LIVING; ANALGESICS, OPIOID; CATHARTICS; CHRONIC DISEASE; COLIC; CONSTIPATION; GASTRIC EMPTYING; GASTROINTESTINAL TRANSIT; HUMANS; PAIN; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34250617568     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01415.x     Document Type: Review

References (47)

1. World Health Organization. Cancer Pain Relief, 2nd edn. Geneva: WHO, 1996.
2. Quigley C. The role of opioids in cancer pain. BMJ 2005 331: 825 9.
3. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004 112: 372 80.
4. The Pain Society. Recommendations for the Appropriate Use of Opioids for Persistent Non-cancer Pain. A Consensus Statement Prepared on Behalf of the Pain Society, the Royal College of Anaesthetists, the Royal College of General Practitioners and the Royal College of Psychiatrists. http://www. britishpainsociety.org/opioids_doc_2004.pdf (accessed 23 April 2007).
5. Klepstad P, Kaasa S, Cherny N, Hanks G, de Conno F. Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat Med 2005 19: 477 84.
6. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006 10: 287 333.
7. IMS Health National Prescription Audit, 2006.
8. IMS Health MIDAS database, 2005.
9. Choi YS, Billings JA. Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage 2002 24: 71 90.
10. Holzer P. Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs 2007 16: 181 94.
11. Mehendale SR, Yuan CS. Opioid-induced gastrointestinal dysfunction. Dig Dis 2006 24: 105 12.
12. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005 7: R1046 51.
13. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001 182: 11S 8S.
14. Gutstein HB, Akil H. Opioid Analgesics. New York, NY: McGraw Hill, 2001 (The Pharmacological Basis of Therapeutics).
15. Walsh TD. Prevention of opioid side effects. J Pain Symptom Manage 1990 5: 362 7.
16. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003 349: 1943 53.
17. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003 63: 649 71.
18. Sternini C, Patierno S, Selmer IS, Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil 2004 16 (Suppl. 2 3 16.
19. Sanger GJ, Tuladhar BR. The role of endogenous opioids in the control of gastrointestinal motility: predictions from in vitro modelling. Neurogastroenterol Motil 2004 16 (Suppl. 2 38 45.
20. De Schepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004 16: 383 94.
21. Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 2004 361: 192 5.
22. Shook JE, Pelton JT, Hruby VJ, Burks TF. Peptide opioid antagonist separates peripheral and central opioid antitransit effects. J Pharmacol Exp Ther 1987 243: 492 500.
23. De Luca A, Coupar IM. Insights into opioid action in the intestinal tract. Pharmacol Ther 1996 69: 103 15.
24. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004 16 (Suppl. 2 17 28.
25. McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control 2004 11: 3 9.
26. Basson M. Constipation. http://www.emedicine.com/med/topic2833.htm (accessed March 2007).
27. Allan L, Hays H, Jensen NH et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001 322: 1154 8.
28. Klepstad P, Borchgrevink PC, Kaasa S. Effects on cancer patients' health-related quality of life after the start of morphine therapy. J Pain Symptom Manage 2000 20: 19 26.
29. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. J Pain 2001 93: 247 57.
30. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006 130: 1480 91.
31. Devulder J, Richarz U, Nataraja SH. Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Curr Med Res Opin 2005 21: 1555 68.
32. Fallon M. Constipation in cancer patients: prevalence, pathogenesis and cost-related issues. Eur J Pain 1999 3: 3 7.
33. Leslie J, Bell T, Annunziata K, Freedman D. Opioid-induced constipation compromises pain management and impacts patients quality of life. Anesthesiology 2006 105: A1490.
34. McNicol E, Horowicz-Mehler N, Fisk RA et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003 4: 231 56.
35. Bell T, Milanova T, Grove G et al. OBD symptoms impair quality of life and daily activities, regardless of frequency and duration of opioid treatment: results of a US patient survey (PROBE survey) The 25th Annual Scientific Meeting of the American Pain Society. San Antonia, TX, USA.
36. Bell T, Milanova T, Grove G, Williamson R, Bolge S. Prevalence, severity and impact of opioid-induced GI side effects on the EU: results of a patient survey. Eur J Pain 2006 10 (Suppl. 1 S173 (Abstract 663)/Poster presented at the 5th Congress of the European Federation of IASP Chapters (EFIC); 13-6 September, 2006, Istanbul, Turkey.
37. Annunziata K, Bell T. Impact of opioid-induced constipation on patients and healthcare resource use. Eur J Pain 2006 10 (Suppl. 1 S172 (Abstract 659)/Poster presented at the 5th Congress of the European Federation of IASP Chapters (EFIC); 13-6 September, 2006, Istanbul, Turkey.
38. Thorpe DM. Management of opioid-induced constipation. Curr Pain Headache Rep 2001 5: 237 40.
39. Slappendel R, Simpson K, Dubois D, Keininger DL. Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain 2006 10: 209 17.
40. Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol 2005 40: 540 51.
41. Hanks GW, Conno F, Cherny N et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001 84: 587 93.
42. Cherny N, Ripamonti C, Pereira J et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001 19: 2542 54.
43. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 2004 CD004847.
44. Weschules DJ, Bain KT, Reifsnyder J et al. Toward evidence-based prescribing at end of life: a comparative analysis of sustained-release morphine, oxycodone, and transdermal fentanyl, with pain, constipation, and caregiver interaction outcomes in hospice patients. Pain Med 2006 7: 320 9.
45. Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician 2006 74: 1347 54.
46. Pettit M. Treatment of gastroesophageal reflux disease. Pharm World Sci 2005 27: 432 5.
47. Überall M, Müller-Schwege G. Opioid-induced constipation - a frequent and distressing side effect in daily practice affecting oral and transdermal opioid applications. Eur J Pain 2006 10 (Suppl. 1 S172 (Abstract 656)/Poster presented at the 5th Congress of the European Federation of IASP Chapters (EFIC); 13-6 September, 2006, Istanbul, Turkey.